Difference between revisions of "Team:NTU-LIHPAO-Taiwan/Collaborations"

Line 851: Line 851:
 
<div class="ContentHolder">
 
<div class="ContentHolder">
  
<div class="Text1" id="First1"><Red>Preparation of Competent Cells (<i>E.coli</i>)</Red></div>
+
<div class="Text1" id="First1"><Red>Collaborations</Red></div>
 
<div class="Text2">
 
<div class="Text2">
<Green>Materials and Reagents :</Green>
+
<Green>iGEM Conference at NCTU</Green>
 
</div>
 
</div>
 +
<div class="Text3">
 +
 +
<i>Escherichia coli</i> DH5α
 +
</div>
 
<div class="Text3">
 
<div class="Text3">
 
<ol class="part2">
 
<ol class="part2">
<li><i>Escherichia coli</i> DH5α</li>
+
<li>Will <i>L. casei</i> secret too many CPP-PYY complexes and cause people unwilling to eat for a long term of time, which might cause malnutrition?</li>
<li>LB broth</li>
+
<li>Will your product affect the sensitivity of hypothalamus to PYY? And is there a safety maximum concentration of PYY in blood?</li>
<li>TB buffer</li>
+
<li>How do you measure the concentration of PYY in blood?</li>
<li>DMSO</li>
+
<li>How long will your product stay in human body?</li>
<li>Liquid nitrogen</li>
+
<li>When should people take the capsule? Before or after meal? And how many times should people take the capsule a day?</li>
 +
<li>How do you measure the concentration of PYY in blood?</li>
 +
<li>Can gastrointestinal tract digest CPP-PYY complex before it gets through intestinal membrane?</li>
 +
<li>Question from TCU: Why not use a patch instead?</li>
 +
<li>Suggestion from ZJU-China:
 +
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) We suggest you change the suicide mechanism, because there’s only one promoter before the gene circuit of CPP-PYY and CI. This might cause <i>L. casei</i> die before it works.
 +
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Will holin and endolysin in the suicide mechanism harm other cells? Why not change suicide mechanism into quorum sensing?</li>
 +
<li>What is your product’s positioning? Is it used as food or as medicine?</li>
 +
<li>As we know, <i>L. casei</i> is prokaryote. Can your CPP-PYY complex fold correctly through <i>L. casei</i>?</li>
 +
<li>Will patients be hungrier after they stop taking capsule?</li>
 +
<li>Will immune response arouse by CPP-PYY complex?</li>
 +
<li>Is there any chance that plasmid transfer to other cells and affect the colony in intestine?</li>
 +
<li>Is pLP825 too small for the three parts of genes to fit in?</li>
 +
<li>We know that appetite is controlled by several chemical compounds, such as PYY and leptin. When the concentration of PYY in blood rises, will the concentration of leptin decrease? Will our body naturally balance out the effect from PYY?</li>
 
</ol>
 
</ol>
 
</div>
 
</div>

Revision as of 05:59, 17 September 2015

NTU-LIHPAO-Taiwan

Collaborations
iGEM Conference at NCTU
Escherichia coli DH5α
  1. Will L. casei secret too many CPP-PYY complexes and cause people unwilling to eat for a long term of time, which might cause malnutrition?
  2. Will your product affect the sensitivity of hypothalamus to PYY? And is there a safety maximum concentration of PYY in blood?
  3. How do you measure the concentration of PYY in blood?
  4. How long will your product stay in human body?
  5. When should people take the capsule? Before or after meal? And how many times should people take the capsule a day?
  6. How do you measure the concentration of PYY in blood?
  7. Can gastrointestinal tract digest CPP-PYY complex before it gets through intestinal membrane?
  8. Question from TCU: Why not use a patch instead?
  9. Suggestion from ZJU-China:        (1) We suggest you change the suicide mechanism, because there’s only one promoter before the gene circuit of CPP-PYY and CI. This might cause L. casei die before it works.        (2) Will holin and endolysin in the suicide mechanism harm other cells? Why not change suicide mechanism into quorum sensing?
  10. What is your product’s positioning? Is it used as food or as medicine?
  11. As we know, L. casei is prokaryote. Can your CPP-PYY complex fold correctly through L. casei?
  12. Will patients be hungrier after they stop taking capsule?
  13. Will immune response arouse by CPP-PYY complex?
  14. Is there any chance that plasmid transfer to other cells and affect the colony in intestine?
  15. Is pLP825 too small for the three parts of genes to fit in?
  16. We know that appetite is controlled by several chemical compounds, such as PYY and leptin. When the concentration of PYY in blood rises, will the concentration of leptin decrease? Will our body naturally balance out the effect from PYY?
Escherichia coli DH5α
Maintained by the iGEM team NTU-LIHPAO-Taiwan    ©2015 NTU-LIHPAO-Taiwan